Literature DB >> 12356736

Transcription factor Sp3 is silenced through SUMO modification by PIAS1.

Alexandra Sapetschnig1, Grigore Rischitor, Harald Braun, Andreas Doll, Marion Schergaut, Frauke Melchior, Guntram Suske.   

Abstract

Sp3 is a ubiquitous transcription factor closely related to Sp1. Here we show that Sp3 is a target for SUMO modification in vivo and in vitro. SUMO modification of Sp3 occurs at a single lysine located between the second glutamine-rich activation domain and the DNA-binding domain. Mutational analyses identified the sequence IKXE as essential for SUMO conjugation to Sp3. We identified the protein inhibitor of activated STAT1 (PIAS1) as an interaction partner of Sp3 and Ubc9. Moreover, PIAS1 strongly stimulated SUMO conjugation to Sp3, thus acting as an E3 ligase for SUMO conjugation to Sp3. All mutations that prevented SUMO modification in vitro strongly enhanced the transcriptional activity of Sp3, showing that SUMO modification silences Sp3 activity. SUMO-modified Sp3 bound to DNA with similar specificity and affinity as unmodified Sp3. However, DNA-bound Sp3 did not act as a substrate for SUMO modification.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356736      PMCID: PMC129032          DOI: 10.1093/emboj/cdf510

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  45 in total

1.  SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.

Authors:  M S Rodriguez; C Dargemont; R T Hay
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

Review 2.  SUMO, ubiquitin's mysterious cousin.

Authors:  S Müller; C Hoege; G Pyrowolakis; S Jentsch
Journal:  Nat Rev Mol Cell Biol       Date:  2001-03       Impact factor: 94.444

Review 3.  Ubiquitin-like proteins: new wines in new bottles.

Authors:  E T Yeh; L Gong; T Kamitani
Journal:  Gene       Date:  2000-05-02       Impact factor: 3.688

Review 4.  SUMO--nonclassical ubiquitin.

Authors:  F Melchior
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

5.  Protein modification by SUMO.

Authors:  R T Hay
Journal:  Trends Biochem Sci       Date:  2001-05       Impact factor: 13.807

6.  Role of SUMO-1-modified PML in nuclear body formation.

Authors:  S Zhong; S Müller; S Ronchetti; P S Freemont; A Dejean; P P Pandolfi
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

7.  Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b.

Authors:  H Hofmann; S Flöss; T Stamminger
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation.

Authors:  N Kotaja; S Aittomäki; O Silvennoinen; J J Palvimo; O A Jänne
Journal:  Mol Endocrinol       Date:  2000-12

9.  Regulation of p53 activity in nuclear bodies by a specific PML isoform.

Authors:  V Fogal; M Gostissa; P Sandy; P Zacchi; T Sternsdorf; K Jensen; P P Pandolfi; H Will; C Schneider; G Del Sal
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

10.  Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).

Authors:  H Poukka; U Karvonen; O A Janne; J J Palvimo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

View more
  91 in total

Review 1.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

2.  Sumoylation of p35 modulates p35/cyclin-dependent kinase (Cdk) 5 complex activity.

Authors:  Anja Büchner; Petranka Krumova; Sundar Ganesan; Mathias Bähr; Katrin Eckermann; Jochen H Weishaupt
Journal:  Neuromolecular Med       Date:  2014-11-13       Impact factor: 3.843

3.  Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy.

Authors:  Sam Holmstrom; Mary E Van Antwerp; Jorge A Iñiguez-Lluhi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-08       Impact factor: 11.205

4.  SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression.

Authors:  Gergana Dobreva; Julia Dambacher; Rudolf Grosschedl
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

5.  Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites.

Authors:  Bo Yu; Pran K Datta; Srilata Bagchi
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

6.  Modification of the erythroid transcription factor GATA-1 by SUMO-1.

Authors:  Licio Collavin; Monica Gostissa; Fabio Avolio; Paola Secco; Antonella Ronchi; Claudio Santoro; Giannino Del Sal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

7.  Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses.

Authors:  Weidong Zhou; Jennifer J Ryan; Huilin Zhou
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

8.  Role of the fission yeast SUMO E3 ligase Pli1p in centromere and telomere maintenance.

Authors:  Blerta Xhemalce; Jacob-S Seeler; Geneviève Thon; Anne Dejean; Benoît Arcangioli
Journal:  EMBO J       Date:  2004-09-09       Impact factor: 11.598

9.  STAT1-deficient mice are resistant to cecal ligation and puncture-induced septic shock.

Authors:  Daniela Herzig; Geping Fang; Tracy E Toliver-Kinsky; Yin Guo; Julia Bohannon; Edward R Sherwood
Journal:  Shock       Date:  2012-10       Impact factor: 3.454

10.  Negative modulation of androgen receptor transcriptional activity by Daxx.

Authors:  Ding-Yen Lin; Hsin-I Fang; Ai-Hong Ma; Yen-Sung Huang; Yeong-Shiau Pu; Guido Jenster; Hsing-Jien Kung; Hsiu-Ming Shih
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.